PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16387752-0	2006	Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids.	Glycosaminoglycans	0-18	cathelicidin antimicrobial peptide	Homo sapiens	57-62	
2559786-4	1989	Dibutyryl cAMP (dbcAMP) elicits a striking increase in the accumulation of Alcian blue, pH 1.0-positive cartilage matrix, and a corresponding three- to fourfold increase in the accumulation of 35S-labeled glycosaminoglycans (GAG) by limb mesenchymal cells cultured in low serum medium at densities greater than confluence (i.e. micromass cultures established with 1-2 x 10(5) cells in 10 microliters of medium).	Glycosaminoglycans	205-223	cathelicidin antimicrobial peptide	Homo sapiens	10-14	
2559786-4	1989	Dibutyryl cAMP (dbcAMP) elicits a striking increase in the accumulation of Alcian blue, pH 1.0-positive cartilage matrix, and a corresponding three- to fourfold increase in the accumulation of 35S-labeled glycosaminoglycans (GAG) by limb mesenchymal cells cultured in low serum medium at densities greater than confluence (i.e. micromass cultures established with 1-2 x 10(5) cells in 10 microliters of medium).	Glycosaminoglycans	225-228	cathelicidin antimicrobial peptide	Homo sapiens	10-14	
31002379-1	2019	AIM: To investigate whether glycosaminoglycans (GAGs) binding to high-dose LL37 eliminates its cytotoxicity to dental pulp cells (hDPCs) whilst retaining undiminished antimicrobial and LPS-neutralizing abilities.	Glycosaminoglycans	28-46	cathelicidin antimicrobial peptide	Homo sapiens	75-79	
28837619-0	2017	LL-37 causes cell death of human nasal epithelial cells, which is inhibited with a synthetic glycosaminoglycan.	Glycosaminoglycans	93-110	cathelicidin antimicrobial peptide	Homo sapiens	0-5	
28837619-4	2017	Recent findings suggest that a synthetic glycosaminoglycan (GM-0111) can protect against LL-37-induced sinonasal mucosal inflammation and cell death in a murine model of acute RS.	Glycosaminoglycans	41-58	cathelicidin antimicrobial peptide	Homo sapiens	89-94	
22028895-7	2011	In the CF lung, polyanionic molecules such as glycosaminoglycans (GAGs) and DNA bind LL-37 and impact negatively on its antibacterial activity.	Glycosaminoglycans	46-64	cathelicidin antimicrobial peptide	Homo sapiens	85-90	
19542465-0	2009	LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline.	Glycosaminoglycans	24-42	cathelicidin antimicrobial peptide	Homo sapiens	0-5	
19542465-7	2009	The endogenous LL-37 in CF BAL fluid is protected from this proteolysis by interactions with glycosaminoglycans, but while this protects LL-37 from proteolysis it results in inactivation of LL-37 antimicrobial activity.	Glycosaminoglycans	93-111	cathelicidin antimicrobial peptide	Homo sapiens	15-20	
19542465-8	2009	By digesting glycosaminoglycans in CF BAL fluid, endogenous LL-37 is liberated and the antimicrobial properties of CF BAL fluid restored.	Glycosaminoglycans	13-31	cathelicidin antimicrobial peptide	Homo sapiens	60-65	
19542465-10	2009	This is also seen in vivo in CF sputum where LL-37 is complexed to glycosaminoglycans but is liberated following nebulized hypertonic saline resulting in increased antimicrobial effect.	Glycosaminoglycans	67-85	cathelicidin antimicrobial peptide	Homo sapiens	45-50	
16387752-6	2006	A slot-binding assay was used to study the effects of inhibitors on the interaction between LL-37 and glycosaminoglycans.	Glycosaminoglycans	102-120	cathelicidin antimicrobial peptide	Homo sapiens	92-97	
16387752-10	2006	The interaction between LL-37 and glycosaminoglycans was abrogated by the cationic polymers DEAE-dextran and chitosan, yielding increased activity of LL-37.	Glycosaminoglycans	34-52	cathelicidin antimicrobial peptide	Homo sapiens	24-29	
16387752-10	2006	The interaction between LL-37 and glycosaminoglycans was abrogated by the cationic polymers DEAE-dextran and chitosan, yielding increased activity of LL-37.	Glycosaminoglycans	34-52	cathelicidin antimicrobial peptide	Homo sapiens	150-155